Alamar Biosciences Says Emory Study Identifies ALS Blood Signature With 98.3% Balanced Accuracy

• Alamar Biosciences announced Emory University research identifying a 10-protein blood signature for ALS using its NULISA technology; results appeared in Nature Communications.
• The signature outperformed neurofilament light chain alone, identifying some ALS patients missed by that marker while reducing false positives.
• The findings remain research-stage, not a clinically validated diagnostic test; researchers plan testing in larger, more diverse patient groups.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alamar Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610281605PRIMZONECNPR____9855408) on October 28, 2026, and is solely responsible for the information contained therein.